Extended Data Fig. 1: TIGIT Receptor occupancy following anti-TIGIT or anti-LAG3 antibody therapy. | Nature Cancer

Extended Data Fig. 1: TIGIT Receptor occupancy following anti-TIGIT or anti-LAG3 antibody therapy.

From: Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial

Extended Data Fig. 1

a. TIGIT receptor occupancy in bone marrow immune cells from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-TIGIT antibody. Data points represent biologically independent samples (TIGIT Resp PreRx: n = 3, TIGIT Resp C1: n = 2, TIGIT Resp C2: n = 3; TIGIT NR PreRx: n = 3; TIGIT NR C1: n = 1, TIGIT NR C2: n = 2). b. TIGIT receptor occupancy in circulating immune cells from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-Lag3 antibody. Data points represent biologically independent samples (LAG3 Resp PreRx: n = 4, LAG3 Resp C1: n = 6, LAG3 Resp C2: n = 2; LAG3 NR PreRx: n = 6; LAG3 NR C1: n = 10, LAG3 NR C2: n = 3). c. TIGIT receptor occupancy in bone marrow immune cells from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-LAG3 antibody. Data points represent biologically independent samples (LAG3 Resp PreRx: n = 2, LAG3 Resp C1: n = 2, LAG3 Resp C2: n = 2; LAG3 NR PreRx: n = 4; LAG3 NR C1: n = 5, LAG3 NR C2: n = 2). Box plots represent median with Q1-Q3 and error bars as min-max. MMI: median metal intensity.

Source data

Back to article page